FIELD: biotechnology.
SUBSTANCE: present invention refers to recombinant multimerized forms of immunoglobulin Fc, and can be used in medicine in therapy of nephritis, arthritis and sickle-cell anemia. Hybrid proteins exist in the form of homodimeric and highly ordered multimer fractions, called stradomers. Peptide homodimer consists of two identical monomers, wherein each monomer contains in direction from N- to C-end: (a) leader sequence, (b) at least one IgG1 Fc domain comprising a hinge region of IgG1, a CH2 domain of IgG1 and an IgG3 domain, and (c) at least one IgG2 hinge region multimerization domain. Fc IgG1 domain is characterized by human EEM or DEL IgG1 polymorphism, three point mutations S267E, H268F and S324T and additional point mutations selected from N297A, or G236R, or G236R and E233P of the Fc IgG1 domain sequence SEQ ID NO: 2 or SEQ ID NO: 3.
EFFECT: invention enables to obtain hybrid proteins capable of multimerization and preferential binding with a complement system component C1q.
18 cl, 63 dwg, 12 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOGLOBULIN CONSTANT REGION FC-RECEPTOR BINDING AGENTS | 2008 |
|
RU2729829C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| THERAPEUTIC FUSION PROTEINS | 2020 |
|
RU2825292C1 |
| ENGINEERED MULTI-SPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS IN THE CH2-CH3 REGION | 2018 |
|
RU2804031C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
